CIBC set a C$18.00 target price on Extendicare (TSE:EXE – Free Report) in a research report sent to investors on Monday morning,BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
EXE has been the subject of a number of other research reports. National Bankshares raised their price objective on shares of Extendicare from C$15.45 to C$16.10 and gave the company an “outperform” rating in a report on Friday, August 8th. National Bank Financial upgraded shares of Extendicare to a “strong-buy” rating in a report on Wednesday, July 16th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of C$14.92.
Read Our Latest Report on Extendicare
Extendicare Stock Up 4.8%
Extendicare Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Monday, September 15th were given a dividend of $0.042 per share. This represents a $0.17 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Friday, August 29th. Extendicare’s dividend payout ratio is currently 50.57%.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Recommended Stories
- Five stocks we like better than Extendicare
- 3 Healthcare Dividend Stocks to Buy
- How The Weak Dollar Is Fueling These Global Stock Surges
- How to Read Stock Charts for Beginners
- 3 Recession-Ready Stocks That Thrive When the Economy Sputters
- Differences Between Momentum Investing and Long Term Investing
- 3 Automation-Focused Stocks Flying Under the Radar
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.